[{"orgOrder":0,"company":"Attgeno","sponsor":"Vinnova","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWEDEN","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Sodium Chloride","moa":"Adrenergic receptor Alpha-2 (ADRA2)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I\/ Phase II","graph3":"Attgeno","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Attgeno \/ Vinnova","highestDevelopmentStatusID":"7","companyTruncated":"Attgeno \/ Vinnova"},{"orgOrder":0,"company":"Norgine","sponsor":"Goldman Sachs Asset Management","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"NETHERLANDS","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Financing","leadProduct":"Sodium Chloride","moa":"||Adrenergic receptor Alpha-2 (ADRA2)","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Norgine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Powder for Solution","sponsorNew":"Norgine \/ Goldman Sachs Asset Management","highestDevelopmentStatusID":"15","companyTruncated":"Norgine \/ Goldman Sachs Asset Management"},{"orgOrder":0,"company":"Entrinsic bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"Sodium Chloride","moa":"||Adrenergic receptor Alpha-2 (ADRA2)","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Entrinsic bioscience","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Entrinsic bioscience \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Entrinsic bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Jeffrey Alan Klein","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Sodium Chloride","moa":"Adrenergic receptor Alpha-2 (ADRA2)","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"Jeffrey Alan Klein","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Jeffrey Alan Klein \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Jeffrey Alan Klein \/ Inapplicable"},{"orgOrder":0,"company":"GCS Ramsay Sant\u00e9","sponsor":"Euraxi Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Inapplicable","leadProduct":"Sodium Chloride","moa":"Adrenergic receptor Alpha-2 (ADRA2)","graph1":"Neurology","graph2":"Phase II","graph3":"GCS Ramsay Sant\u00e9","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"GCS Ramsay Sant\u00e9 \/ Euraxi Pharma","highestDevelopmentStatusID":"8","companyTruncated":"GCS Ramsay Sant\u00e9 \/ Euraxi Pharma"},{"orgOrder":0,"company":"Norgine","sponsor":"Faes Farma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"NETHERLANDS","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Agreement","leadProduct":"Potassium Chloride","moa":"||Solute carrier family 12 member 1 (SLC12A1)","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Norgine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Norgine \/ Faes Farma","highestDevelopmentStatusID":"15","companyTruncated":"Norgine \/ Faes Farma"},{"orgOrder":0,"company":"Cambridge University Hospitals NHS Foundation Trust","sponsor":"Antaros Medical","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Sodium Chloride","moa":"Adrenergic receptor Alpha-2 (ADRA2)","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Cambridge University Hospitals NHS Foundation Trust","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cambridge University Hospitals NHS Foundation Trust \/ Antaros Medical","highestDevelopmentStatusID":"11","companyTruncated":"Cambridge University Hospitals NHS Foundation Trust \/ Antaros Medical"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Inapplicable","leadProduct":"Sodium Chloride","moa":"Adrenergic receptor Alpha-2 (ADRA2)","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase IV","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"NYU Langone Health \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"NYU Langone Health \/ Inapplicable"},{"orgOrder":0,"company":"Agitated Solutions","sponsor":"Bright Research Partners","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2025","type":"Inapplicable","leadProduct":"Sodium Chloride","moa":"Adrenergic receptor Alpha-2 (ADRA2)","graph1":"Undisclosed","graph2":"Phase III","graph3":"Agitated Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Agitated Solutions \/ Bright Research Partners","highestDevelopmentStatusID":"10","companyTruncated":"Agitated Solutions \/ Bright Research Partners"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Sodium Chloride","moa":"Adrenergic receptor Alpha-2 (ADRA2)","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"NYU Langone Health \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NYU Langone Health \/ Inapplicable"},{"orgOrder":0,"company":"Suzana Erico Tanni Minamoto","sponsor":"Liita Care ApS","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Sodium Chloride","moa":"Adrenergic receptor Alpha-2 (ADRA2)","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Suzana Erico Tanni Minamoto","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Powder","sponsorNew":"Suzana Erico Tanni Minamoto \/ Liita Care ApS","highestDevelopmentStatusID":"8","companyTruncated":"Suzana Erico Tanni Minamoto \/ Liita Care ApS"},{"orgOrder":0,"company":"University of Galway","sponsor":"Health Research Board, Ireland","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Inapplicable","leadProduct":"Sodium Chloride","moa":"Adrenergic receptor Alpha-2 (ADRA2)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"University of Galway","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"University of Galway \/ Health Research Board, Ireland","highestDevelopmentStatusID":"8","companyTruncated":"University of Galway \/ Health Research Board, Ireland"},{"orgOrder":0,"company":"BioAegis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Inapplicable","leadProduct":"Sodium Chloride","moa":"Adrenergic receptor Alpha-2 (ADRA2)","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"BioAegis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioAegis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioAegis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"BAT6026","moa":"||OX40 receptor","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bio-Thera Solutions \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Bio-Thera Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Sodium Chloride","moa":"Adrenergic receptor Alpha-2 (ADRA2)","graph1":"Undisclosed","graph2":"Phase I","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Daewoong Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Daewoong Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Sodium Chloride","moa":"Adrenergic receptor Alpha-2 (ADRA2)","graph1":"Undisclosed","graph2":"Phase I","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Sunnybrook Health Sciences Centre","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sodium Chloride","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Sunnybrook Health Sciences Centre","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Sunnybrook Health Sciences Centre \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sunnybrook Health Sciences Centre \/ Inapplicable"},{"orgOrder":0,"company":"Sunnybrook Health Sciences Centre","sponsor":"Terry Fox Research Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sodium Chloride","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Sunnybrook Health Sciences Centre","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Sunnybrook Health Sciences Centre \/ Terry Fox Research Institute","highestDevelopmentStatusID":"6","companyTruncated":"Sunnybrook Health Sciences Centre \/ Terry Fox Research Institute"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Sodium Chloride","moa":"Apolipoprotein C-III mRNA 3'UTR","graph1":"Nephrology","graph2":"Undisclosed","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NYU Langone Health \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"NYU Langone Health \/ Inapplicable"}]
Find Clinical Drug Pipeline Developments & Deals for Sodium Chloride
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
Aspen API. More than just an API™
